Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
Toxicity doesn't stop Incyte
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
